Comparison of bleomycin polidocanol foam versus electrochemotherapy combined with polidocanol foam for treatment of venous malformations.

OBJECTIVE: This study aims to investigate the difference in safety and efficacy between two treatments for venous malformations (VMs), electrochemotherapy combined with polidocanol foam (ECP) and bleomycin polidocanol foam (BPF), providing alternative therapies for VMs.

METHODS: We conducted a retrospective review of 152 patients with venous malformations treated with ECP and BPF. Pre- and post-treatment MRI were collected, and clinical follow-up assessments were performed. Imaging results were used to calculate lesion volume changes. Clinical outcomes included changes in pain and improvements in perceived swelling. Patients were followed up at 1 week and 6 months after surgery. All emerging complications were documented in detail.

RESULTS: Of the 152 patients, 87 (57.2%) received BPF treatment, 65 (42.8%) received ECP treatment. The most common location of venous malformations was the lower extremities (92/152[60.2%]), and the most common symptom was pain (108/152[71.1%]).Forty-three patients had previously undergone therapy in the BPF group (43/87[49.4%]), while 30 patients had received prior treatment in the ECP group (30/65[46.2%]). The study found that the percentage of lesion volume reduction in the BPF group was not significantly different from that in the ECP group (75.00±17.85% vs 74.69±8.48%, P = 0.899). ECP was more effective when the initial lesion volume was greater than 30 mL (67.66±12.34% vs 73.47±8.00%, P = 0.048). Patients treated with BPF had significantly less posttreatment pain than those treated with ECP, in different baseline lesion size. In the overall sample, pain relief was significantly higher in the BPF group than in the ECP group (4.21 ± 1.19 vs 3.57 ± 0.76, P = 0.002). However, there was no difference in pain relief between the two groups for the treatment of initially large venous malformations (4.20 ± 0.94 vs 3.70 ± 0.87, P = 0.113). The ECP group was significantly more likely to develop hyperpigmentation (5/87 [5.75%] vs 11/65 [16.92%], P = 0.026) and swelling (9/87 [10.34%] vs 16/65 [24.62%], P = 0.019) 1 week after surgery than the BPF group.

CONCLUSION: Our study demonstrates that both BPF and ECP are effective treatments for VMs, with BPF being a safer option. ECP, is a better choice for patients with the initial lesion volume greater than 30 mL, but it is more likely to lead to early swelling and hyperpigmentation.